ANDA 203591, held by Sofie. Fludeoxyglucose F-18.
As of Nov 16, 2026, ANDA 203591 (Fludeoxyglucose F18), held by Sofie, was first approved by FDA on Aug 31, 2015, with 1 approved supplement and 0 published complete response letters.
1. INDICATIONS AND USAGE Fludeoxyglucose F18 Injection, USP is indicated for positron emission tomography (PET) imaging in the following settings: Fludeoxyglucose F 18 Injection, USP, is
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 31, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fludeoxyglucose F1820-300mCi/ML · injectable;intravenous | Fludeoxyglucose F-18 | Rx |
| Mar 15, 2021 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 31, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters